UI Hospitals and Clinics

Clinical Trial Details

Short Title
Multicenter, Single-Arm Study to Evaluate Efficacy & Safety of Single Agent BTK inhibit
Official Title

A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy, MCL-2001


Participants in this study have been diagnosed with Mantle Cell Lymphoma (MCL), which has been previously treated and the disease has returned. The purpose of the study is to assess the effects (both good and bad) of Ibrutinib in MCL and whether the MCL responds to treatment. The Study treatment is a maximum of 3 years, depending on how well the participant responds to treatment.

Start Date
January 10, 2013
End Date
March 22, 2013
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Lori Rosenstein, MD
Contact Info

Mary Schall 319-356-3516

Department or Field of Study
cancer ; Ibrutinib ; IRB#201207512 ; Mantle Cell Lymphoma (MCL) ; MCL-2001 ; phase II ; phase two ; rosenstein ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.